Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase II abatacept study in primary Sjögren's syndrome
NL-OMON34695Phase 2Recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Aug 2010
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of abatacept in primary Sjögren's syndrome, sponsored by University Medical Center Groningen. Primary endpoints: Stimulated whole saliva flow rate at 24 weeks and Safety of abatacept treatment. Started Aug 2010; status: recruiting.
02
Drugs
abatacept
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on NL-OMON34695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34695.